Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 365 clinical trials
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

To evaluate the efficacy,safety and immunogenicity of TQ-B211 plus docetaxel versus Herceptin plus docetaxel in Patients with HER2-positive metastatic breast cancer.Trastuzumab plus docetaxel was chosen as the comparator in the control group,as it represents a common first-line treatment option used in HER2+ MBC population in China.

  • 0 views
  • 25 Jan, 2021
  • 2 locations
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for study.

stage iv breast cancer
metastasis
endocrine therapy
fulvestrant
aromatase inhibitor
  • 34 views
  • 23 Jan, 2021
  • 4 locations
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.

HER2
cancer therapy
anastrozole
stage iv breast cancer
  • 0 views
  • 25 Jan, 2021
Study of the Impact of DPD Activity on the Efficacy of Capecitabine

This study evaluates the Impact of DihydroPyrimidine Dehydrogenase (DPD) activity on the efficacy of Capecitabine in patients with metastatic breast cancer. The DPD phenotype before the

stage iv breast cancer
cancer
breast cancer
  • 0 views
  • 27 Jan, 2021
  • 5 locations
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with …

  • 38 views
  • 27 Jan, 2021
  • 52 locations
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

local therapy
metastasis
neutrophil count
mirena
gilbert's syndrome
  • 45 views
  • 24 Jan, 2021
  • 3 locations
Enhancing Shared Decision-Making in Breast Cancer

(delayed delivery of standard-of-care TPs) to determine impact on SDM. The intervention will be piloted in a RCT with 140 early stage breast cancer (EBC) and 140 metastatic breast cancer (MBC) patients to

  • 0 views
  • 23 Jan, 2021
  • 1 location
Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

, Bhutan, United Arab Emirates, Nepal, New Zealand, Japan, Russia, Sri Lanka, Argentina, Hong Kong, and Lebanon for the treatment of patients with metastatic breast cancer. ABRAXANE is also approved for

renal function
fluorouracil
paclitaxel
tumor cells
cancer
  • 0 views
  • 22 Jan, 2021
  • 1 location
Ribociclib and Letrozole Treatment in Ovarian Cancer

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

  • 26 views
  • 03 Feb, 2021
  • 26 locations
Sacituzumab Govitecan in Chinese Patients With mTNBC of at Least 2 Prior Treatments

The purpose of this study is to evaluate the efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (TNBC) who received at least two prior chemotherapy treatments.

  • 0 views
  • 26 Jan, 2021
  • 1 location